SEARCH

SEARCH BY CITATION

References

  • Bull D. R., Palij P., Sheehan M. J., Millar J., Stamford J. A., Kruk Z. L. and Humphrey P. P. A. (1990) Application of fast cyclic voltammetry to measurement of electrically evoked dopamine overflow from brain slices in vitro. J. Neurosci. Meth. 32, 3744.
  • Butcher S. P., Fairbrother I. S., Kelly J. S. and Arbuthnott G. W. (1988) Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 50, 346355.
  • Butkerait P. and Friedman E. (1993) Repeated reserpine increases striatal dopamine receptor and guanine nucleotide binding protein RNA. J. Neurochem. 60, 566571.
  • Chan P. M. (2002) Molecular and behavioural studies on a mouse model with impaired monoamine storage. PhD Thesis, University of Cambridge, UK.
  • Chan P. M., Mooslehner K., Keverne E. B. and Emson P. C. (2000) Studies of basal and amphetamine stimulated dopamine release in the dorsal striatum of a vesicular monoamine transporter (VMAT2) mutant mouse. Soc. Neurosci. Abstr. 26, 344.7.
  • Erickson J. D. and Eiden L. E. (1993) Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61, 23142317.
  • Erickson J. D., Eiden L. E. and Hoffman B. J. (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl Acad. Sci. USA 89, 1099310997.
  • Ewing A. G., Bigelow J. C. and Wightman R. M. (1983) Direct in vivo monitoring of dopamine released from two striatal compartments in the rat. Science 221, 169171.
  • Fon E. A., Pothos E. N., Sun B.-C., Killeen N., Sulzer D. and Edwards R. H. (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 12711283.
  • Gainetdinov R. R., Fumagalli F., Wang Y. M., Jones S. R., Levey A. I., Miller G. W. and Caron M. G. (1998) Increase MPTP toxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70, 19731978.
  • German D. C., Liang C.-L., Manaye K. F., Lane K. and Sonsalla P. K. (2000) Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101, 10631069.
  • Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature379, 606–612.
  • Gordon I., Weizman R. and Rehavi M. (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur. J. Pharmacol. 298, 2730.
  • Green A. L. and El Haut M. J. (1978) Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo. J. Pharm. Pharmacol. 30, 262263.
  • Iravani M. M. and Kruk Z. L. (1995) Effects of amphetamine on carrier-mediated and electrically stimulated dopamine release in slices of rat caudate putamen and nucleus accumbens. J. Neurochem. 64, 11611168.
  • Jones S. R., Gaindetdinov R. R., Wightman R. M. and Caron M. G. (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 19791986.
  • Kilbourn M. R., Sherman P. S. and Pisani T. (1992) Repeated reserpine administration reduces in vivo[18F]GBR 13119 binding to the dopamine uptake site. Eur. J. Pharmacol. 261, 109112.
  • Kim D. S., Szczypka M. S. and Palmiter R. D. (2000) Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J. Neurosci. 20, 44054413.
  • Langer S. Z. and Arbilla S. (1984) The amphetamine paradox in dopaminergic transmission. Trends Pharmacol. Sci. 5, 387390.
  • Leviel V. (2001) The reverse transport of DA, what physiological significance? Neurochem. Int. 38, 83106.
  • Liu Y., Peter D., Roghani A., Schuldiner S., Prive G. G., Eisenberg D., Brecha N. and Edwards R. H. (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70, 539551.
  • Miller G. W., Gainetdinov R. R., Levey A. I. and Caron M. G. (1999) Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20, 424429.
  • Miller H. H., Shore P. A. and Clarke D. E. (1980) In vivo monoamine oxidase inhibition by d-amphetamine. Biochem. Pharmacol. 29, 13471354.
  • Missale C., Nisoli E., Liberini P., Rizzonelli P., Memorandum M., Buonamici M., Rossi A. and Spano P. (1989) Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding. Brain Res. 483, 117122.
  • Mooslehner K. A., Chan P. M., Xu W., Liu L., Smadja C., Humby T., Allen N. D., Willkinson L. S. and Emson P. C. (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for Parkinsonism. Mol. Cell Biol. 21, 53215331.
  • Neisewander J. L., Lucli I. and McGonigle P. (1991) Behavioural and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257, 850860.
  • Patel J., Trout S. J. and Kruk Z. L. (1992) Regional differences in evoked dopamine efflux in brain slices of rat anterior and posterior caudate putamen. NS Arch. Pharmacol. 346, 267276.
  • Patel J., Trout S. J., Palij P., Whelpton R. and Kruk Z. L. (1995) Biphasic inhibition of stimulated endogenous dopamine release by 7-OH-DPAT in slices of rat nucleus accumbens. Br. J. Pharmacol. 115, 421–426.
  • Paxinos G. and Franklin K. B. J. (2001) The Mouse Brain in Sterotaxic Coordinates, pp. 70 (Figure 20). Academic Press, San Diego.
  • Rubenstein M., Muschietti J. P., Gershanik O., Flawia M. M. and Stepano F. J. (1990) Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J. Pharmacol. Exp. Ther. 252, 810816.
  • Schmitz Y., Lee J. C., Schmauss C., Gonon F. and Sulzer D. (2001) Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21, 59165924.
  • Schuldiner S. (1994) A molecular glimpse of vesicular monoamine transporters. J. Neurochem. 62, 20672078.
  • Shore P. A. (1976) Actions of amfonelic acid and other non-amphetamine stimulants on the dopamine neurone. J. Pharm. Pharmacol. 28, 855877.
  • Speciale S. G., Liang C.-L., Sonsalla P. K., Edwards R. H. and German D. C. (1998) The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84, 11771185.
  • Stanwood G. D., Lucki I. and McGonigle P. (2000) Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J. Pharmacol. Exp. Ther. 295, 12321240.
  • Sulzer D. and Rayport S. (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797808.
  • Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S. and Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 41024108.
  • Takahashi N., Miner L. L., Sora I., Ujike H., Revay R. S., Kostic V., Jackson-Lewis V., Przedborski S. and Uhl G. R. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA 94, 99389943.
  • Wang Y.-M., Gainetdinov R. R., Fumagalli F., Xu F., Jones S. R., Bock C. B., Miller G. W., Wightman R. M. and Caron M. G. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 12851296.
  • Wieczorek W. J. and Kruk Z. L. (1994) Differential actions of (+)-amphetamine on electrically evoked dopamine overflow in rat brain slices containing corpus striatum and nucleus accumbens. Br. J. Pharmacol. 111, 829836.
  • Zahniser N. R. and Doolen S. (2001) Chronic and acute regulation of Na+/Cl-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol. Ther.92, 21–55.
  • Zhou Q. Y. and Palmiter R. D. (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 11971209.